1. 082 DAY CASE PACEMAKER IMPLANTATION FEASIBLE ACCEPTABLE AND SAFE. (24th May 2013) Authors: Brahmbhatt, D H; Chari, A; Prasad, R; Nayar, V; Cantelon, P; Belham, M R D; Pugh, PJ Journal: Heart Issue: Volume 99(2013)Supplement 2 Page Start: A50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 133 Neurosurgery Education in The Medical School Curriculum: A Scoping Review. (4th May 2021) Authors: Lee, K S; Zhang, J J Y; Alamri, A; Chari, A Journal: British journal of surgery Issue: Volume 108(2021)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 607 A Career in Neurosurgery: Perceptions and the Impact of a National SBNS/NANSIG Neurosurgery Careers Day. (19th August 2022) Authors: Solomou, G; Venkantesh, A; Patel, W; Chari, A; Mohan, M; Bandyopadhyay, S; Gillespie, C; Mendoza, N; Watts, C; Jenkins, A Journal: British journal of surgery Issue: Volume 109(2022)Supplement 6 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 77 The Development of Core Outcome Sets and Common Data Elements in Clinical Neurosciences: A Scoping Review. (4th May 2021) Authors: Horsfall, H L; Bandyopadhyay, S; Chari, A; Kolias, A Journal: British journal of surgery Issue: Volume 108(2021)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY. (5th April 2022) Authors: Rodriguez-Otero, P; Dholaria, B; Askari, E; Reece, D; van de Donk, N; Chari, A; Goldschmidt, H; Krishnan, A; Martin, T; Mateos, M; Morillo, D; Rodriguez, C; Rosinol, L; San-Miguel, J; Balari, A; Wäsch, R; Weisel, K; Verona, R; Lin, S; Prior, T Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS. (5th April 2022) Authors: Mateos, M; Hari, P; Bahlis, N; Chari, A; van de Donk, NWCJ; Dholaria, B; Garfall, AL; Goldschmidt, H; Kortüm, KM; Krishnan, A; Martin, T; Morillo, D; Oriol, A; Reece, D; Rodriguez, C; Rodríguez-Otero, P; San-Miguel, JF; Usmani, SZ; Verona, R; Lin, SXW Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (5th April 2022) Authors: Popat, R; Usmani, S; Garfall, A; van de Donk, N; Nahi, H; San-Miguel, J; Oriol, A; Nooka, A; Martin, T; Rosinol, L; Chari, A; Karlin, L; Benboubker, L; Mateos, M; Bahlis, N; Moreau, P; Besemer, B; Martínez-López, J; Sidana, S; Pei, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1. (5th April 2022) Authors: van de Donk, N. W. C. J; Minnema, M C; Berdeja, J G; Oriol, A; Krishnan, A; Rodríguez-Otero, P; Askari, E; Mateos, M; Costa, L. J; Verona, R; Ma, J; Girgis, S; Yang, S; Hilder, B. W; Russell, J; Goldberg, J. D; Chari, A Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?. (5th April 2022) Authors: Popat, R; Badros, A; Kumar, S; Rodriguez-Otero, P; Cohen, A; Manier, S; Voorhees, P; Gay, F; Rifkin, R; Martin, T; Chari, A; Weisel, K; Farooq, A; Jeng, B; Chng, W; Lee, H; Berdeja, J; Jadhav, V; Tosolini, A; Eliason, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗